Greg Weaver is recorded as CFO at AtaiBeckley Inc., CFO at Altimmune, Inc. (ALT) and CFO at Atossa Therapeutics, Inc. (ATOS) since June 1, 2023. Altimmune, Inc. reported in an 8-K filed November 12, 2024 that Greg Weaver was appointed Chief Financial Officer (CFO), effective November 11, 2024. Atossa Therapeutics, Inc. reported in an 8-K filed October 6, 2023 that Greg Weaver resigned as member of the Board of Directors, effective October 5, 2023. Atossa Therapeutics, Inc. reported in an 8-K filed October 6, 2023 that Greg Weaver resigned as Executive Vice President and Chief Financial Officer, effective October 5, 2023. Equibles holds 4 filed executive changes naming Greg Weaver; each is listed under recent activity with its source filing. The proxy statement of Atossa Therapeutics, Inc. reports total compensation of $2,379,426 for Greg Weaver in fiscal 2023, including a base salary of $197,756. Greg Weaver has spoken on 9 earnings calls and 3 other investor events across 2 companies, most recently for Altimmune, Inc. on September 10, 2026. Those appearances were for Altimmune, Inc. (ALT) and AtaiBeckley Inc.. Altimmune, Inc. is classified in the Biotechnology industry within the Healthcare sector. AtaiBeckley Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Altimmune, Inc. includes Jerome Durso (CEO and Board Member), Vipin K. Garg (CEO), William Enright (CEO) and 7 others.
“Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective immediately.”
Altimmune, Inc. Form 8-K, filed November 12, 2024
· Read the filing
“Pursuant to his employment agreement with the Company, dated as of June 1, 2023, Mr. Weaver's termination of service as an employee served as his resignation from all other positions with the Company, including as a member of the Board of Directors.”
Atossa Therapeutics, Inc. Form 8-K, filed October 6, 2023
· Read the filing
Greg Weaver on recent calls
“Mohit, we've got first of the balance sheet today. At the end of June, reported out $519 million in cash. So that's a runway that takes us full on through the readout in MASH in 2029, importantly.”
“Starting with our financial results for the quarter, which were in line with our expectations. R&D expense in Q2 26 was $18.7 million compared to $17.2 million for the same period prior year.”
“Eighteen months into the CFO role, and it really is early days. I remember it was really about the financial situation, what it's going to take to get through that MASH phase three, where we were and how we get there, what optionality we had, investor engagement.”
“Yeah, let me start with sort of how I think about the financing strategy as we came into the year. We had a pretty good line of sight on what the investment in the match trial was going to take.”
“Starting with the balance sheet here, a key strategic focus for the company was securing access to the capital required to successfully drive our clinical programs.”
